Peptron펩트론
087010 · KOSDAQ · ₩087010 · 펩트론
₩92,300▼ ₩4,900 (5.04%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩1.4B | ₩2B | ₩987M | ₩1.6B | ₩1.4B | ₩1.6B | ₩1.5B | ₩588M |
| Cost of sales | ₩2B | ₩1.4B | ₩2.3B | ₩625M | ₩610M | ₩593M | ₩784M | ₩446M |
| Gross profit | −₩535M | ₩578M | −₩1.3B | ₩977M | ₩816M | ₩1B | ₩761M | ₩143M |
| Operating income | −₩7.9B | −₩5.8B | −₩5.7B | −₩6.2B | −₩5B | −₩4.4B | −₩3.5B | −₩4.7B |
| Net income | −₩7.7B | −₩6.1B | −₩4.7B | −₩2B | −₩3.8B | −₩3.3B | −₩5B | −₩4.8B |
| Net income to shareholders | −₩7.7B | −₩6.1B | −₩4.7B | −₩2B | −₩3.8B | −₩3.3B | −₩5B | −₩4.8B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₩168B | ₩174B | ₩179B | ₩184B | ₩162B | ₩165B | ₩169B | ₩41B |
| Current assets | ₩82B | ₩94B | ₩115B | ₩116B | ₩107B | ₩122B | ₩126B | ₩7.1B |
| Cash and equivalents | ₩12B | ₩11B | ₩4.4B | ₩1.5B | ₩872M | ₩655M | ₩1B | ₩1.5B |
| Total liabilities | ₩39B | ₩38B | ₩37B | ₩37B | ₩18B | ₩16B | ₩17B | ₩20B |
| Current liabilities | ₩9B | ₩7.7B | ₩7B | ₩7.3B | ₩4.8B | ₩4.2B | ₩5.1B | ₩7B |
| Borrowings | ₩30B | ₩30B | ₩29B | ₩30B | ₩9B | ₩8.1B | ₩9B | ₩13B |
| Total equity | ₩129B | ₩136B | ₩142B | ₩146B | ₩144B | ₩148B | ₩152B | ₩21B |
| Shareholders' equity | ₩129B | ₩136B | ₩142B | ₩146B | ₩144B | ₩148B | ₩152B | ₩21B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −₩3.6B | −₩4.4B | −₩4.9B | −₩7.3B | −₩3.9B | −₩4.5B | −₩2.4B | −₩4B |
| Capital spending | ₩722M | ₩6.6B | ₩1.5B | ₩373M | ₩592M | ₩1.3M | ₩287M | ₩302M |
| Free cash flow | −₩4.4B | −₩11B | −₩6.4B | −₩7.7B | −₩4.5B | −₩4.5B | −₩2.7B | −₩4.3B |
Consolidated where available. Amounts in won.
Also known as: Peptron / 펩트론 / 087010 / KRX:087010
Source: KRX statistical information